Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
Oncology · 11.10.2024 · 103 (6) · 456-468
DOI: 10.1159/000541018 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Oncology, online erschienen am 11.10.2024. Verfasst von Mara Persano und 59 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, A. Businco Cancer Center, A. R. N. A. S. Brotzu, Cagliari, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Sorafenib. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Introduction
The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries is sorafenib, due to the lack of reimbursement for other drugs. Several randomized trials are currently underway to clarify the best second-line therapy in patients with HCC. This real-world study aimed to compare outcomes reached by lenvatinib and sorafenib second-line therapy in this setting.
Methods
The overall cohort included 891 patients with HCC from 5 countries treated with atezolizumab plus bevacizumab in first-line setting between October 2018 and April 2022. At the data cut-off (May 2022), 41.5% of patients were continuing a first-line treatment, 5.5% were lost at follow-up, and 53.0% of patients had progressive disease after first-line therapy. 51.5% of patients with progressive disease received a second-line treatment, while 48.5% did not receive any subsequent therapy. Between patients receiving second-line treatment, 11.1% of patients underwent transarterial chemoembolization, 21.0% received sorafenib, 35.4% underwent lenvatinib, and 32.5% were treated with other drugs.
Results
Lenvatinib second-line subgroup achieved a median overall survival (mOS) of 18.9 months, significative longer (p = 0.01; hazard ratio [HR]: 2.24) compared to sorafenib subgroup that reached a mOS of 14.3 months. The multivariate analysis highlighted albumin-bilirubin 1 grade (p < 0.01; HR: 5.23) and lenvatinib second-line therapy (p = 0.01; HR: 2.18) as positive prognostic factors for OS. The forest plot highlighted a positive trend in terms of OS in favor of patients treated with lenvatinib second-line regardless of baseline characteristics before first-line therapy.
Conclusion
These results suggest that, in patients with HCC progressed to first-line atezolizumab plus bevacizumab, lenvatinib second-line therapy is associated to an improved survival compared to sorafenib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, A. Businco Cancer Center, A. R. N. A. S. Brotzu, Cagliari, Italy.
- Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
- Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Zitieren
APA
Persano, M., Casadei-Gardini, A., Tada, T., Suda, G., Shimose, S., Kudo, M., Rossari, F., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., Masi, G., Bergamo, F., Amadeo, E., Vitiello, F., Kumada, T., Sakamoto, N., Iwamoto, H., …, & Okubo, T. (2024). Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study. Oncology, 103(6), 456-468. https://doi.org/10.1159/000541018
Vancouver
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, et al. Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study. Oncology. 2024;103(6):456-468. doi:10.1159/000541018
BibTeX
@article{Persano2024,
author = {Persano, Mara and Casadei-Gardini, Andrea and Tada, Toshifumi and Suda, Goki and Shimose, Shigeo and Kudo, Masatoshi and Rossari, Federico and Yoo, Changhoon and Cheon, Jaekyung and Finkelmeier, Fabian and Lim, Ho Yeong and Presa, José and Masi, Gianluca and Bergamo, Francesca and Amadeo, Elisabeth and Vitiello, Francesco and Kumada, Takashi and Sakamoto, Naoya and Iwamoto, Hideki and Aoki, Tomoko and Chon, Hong Jae and Himmelsbach, Vera and Iavarone, Massimo Alberto and Cabibbo, Giuseppe and Montes, Margarida and Foschi, Francesco Giuseppe and Vivaldi, Caterina and Soldà, Caterina and Sho, Takuya and Niizeki, Takashi and Nishida, Naoshi and Steup, Christoph and Bruccoleri, Mariangela and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Ochi, Hironori and Yasuda, Satoshi and Toyoda, Hidenori and Ogawa, Chikara and Nishimura, Takashi and Hatanaka, Takeshi and Kakizaki, Satoru and Shimada, Noritomo and Kawata, Kazuhito and Hiraoka, Atsushi and Tada, Fujimasa and Ohama, Hideko and Nouso, Kazuhiro and Morishita, Asahiro and Tsutsui, Akemi and Nagano, Takuya and Itokawa, Norio and Okubo, Tomomi},
title = {Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study},
journal = {Oncology},
year = {2024},
volume = {103},
number = {6},
pages = {456--468},
doi = {10.1159/000541018}
}
EUVIMED